Table 3.
Post-transplant outcomes of included studies.
| Study | ITBLs (tPA vs. Non tPA) | Total Biliary Complications (tPA vs. Non-tPA) | Bile Leak (tPA vs. Non-tPA) | Anastomotic Strictures (tPA vs. Non-tPA) | HAT (tPA vs. Non-tPA) | Blood Transfusion (pRBC) (tPA vs. Non-tPA) | Graft Survival (1-Year) (tPA vs. Non-tPA) | Patient Survival (1-Year) (tPA vs. Non-tPA) |
|---|---|---|---|---|---|---|---|---|
| Seal (2014) [23] | 2/85 (2.35%) vs. 7/33 (21.21%) (P = 0.002) |
14/85 (16.47%) vs. 11/33 (33.33%) (P = 0.02) |
NA | NA | NA | 3.2 ± 3.4 vs. 3.1 ± 2.3 (P = 0.74) | 82/85 (96.47%) vs. 23/33 (69.69%) (P < 0.001) |
83/85 (97.64%) vs. 29/33 (87.87%) (P = 0.08) |
| Eghtesad (Randomized + non-randomized) (2015) [33] | 1/34 (2.94%) vs. 1/46 (2.17%) (P = 0.83) |
NA | NA | NA | 1/34 (2.94%) vs. 3/46 (6.52%) (P = 0.40) |
NA | NA | NA |
| Kubal (2016) [21] | 0/30 (0%) vs. 11/61 (18.03%) (P = 0.01) |
8/30 (26.66%) vs. 43/61 (70.50%) (P < 0.001) |
1/30 (3.33%) vs. 4/61 (6.51%) (P = 0.85) |
7/30 (23.33%) vs. 28/61 (45.90%) (P = 0.06) |
0/30 (0%) vs. 2/61 (3.27%) (P = 0.80) |
4.2 ± 3.2 vs. 7.2 ± 6.0 (P = 0.01) | 26/30 (86.67%) vs. 49/61 (80.32%) (P = 0.14) |
26/30 (86.67%) vs. 53/61 (86.88%) (P = 0.90) |
| Bohorquez (2017) [24] | 3/100 (3.0%) vs. 2/38 (5.26%) (P = 0.63) |
25/100 (25.0%) vs. 9/38 (23.68%) (P = 0.87) |
5/100 (5.0%) vs. 2/38 (5.26%) (P = 0.89) |
19/100 (19.0%) vs. 5/38 (13.15%) (P = 0.42) |
3/100 (3.0%) vs. 3/38 (7.89%) (P = 0.20) |
3.4 ± 4.4 vs. 4.5 ± 3.8 (P = 0.16) | 92/100 (92.0%) 29/38 (76.31%) (P = 0.02) |
93/100 (93.0%) vs. 33/38 (86.84%) (P = 0.41) |
Non-tPA, non-tissue plasminogen activator group (non-thrombolytic group); tPA, tissue plasminogen activator group (thrombolytic group); ITBLs, ischemic-type biliary lesion; HAT, hepatic artery thrombosis; pRBC, packed red blood cells; NA, not applicable.